Microbiome—Friend or Foe of Pancreatic Cancer?
Pancreatic ductal adenocarcinoma is one of the deadliest human neoplasms. Despite the development of new surgical and adjuvant therapies, the prognosis remains very poor, with the overall survival rate not exceeding 9%. There is now increasing evidence that the human microbiome, which is involved in...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/23/5624 |
| _version_ | 1797507662515011584 |
|---|---|
| author | Jaroslaw Daniluk Urszula Daniluk Pawel Rogalski Andrzej Dabrowski Agnieszka Swidnicka-Siergiejko |
| author_facet | Jaroslaw Daniluk Urszula Daniluk Pawel Rogalski Andrzej Dabrowski Agnieszka Swidnicka-Siergiejko |
| author_sort | Jaroslaw Daniluk |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma is one of the deadliest human neoplasms. Despite the development of new surgical and adjuvant therapies, the prognosis remains very poor, with the overall survival rate not exceeding 9%. There is now increasing evidence that the human microbiome, which is involved in many physiological functions, including the regulation of metabolic processes and the modulation of the immune system, is possibly linked to pancreatic oncogenesis. However, the exact mechanisms of action are poorly understood. Our review summarizes the current understanding of how the microbiome affects pancreatic cancer development and progression. We discuss potential pathways of microbe translocation to the pancreas, as well as the mechanism of their action. We describe the role of the microbiome as a potential marker of pancreatic cancer diagnosis, progression, and survival. Finally, we discuss the possibilities of modifying the microbiome to improve treatment effectiveness for this deadly disease. |
| first_indexed | 2024-03-10T04:51:40Z |
| format | Article |
| id | doaj.art-c2fd702354fa40c4a50d1db37bc67c8a |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:51:40Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-c2fd702354fa40c4a50d1db37bc67c8a2023-11-23T02:36:56ZengMDPI AGJournal of Clinical Medicine2077-03832021-11-011023562410.3390/jcm10235624Microbiome—Friend or Foe of Pancreatic Cancer?Jaroslaw Daniluk0Urszula Daniluk1Pawel Rogalski2Andrzej Dabrowski3Agnieszka Swidnicka-Siergiejko4Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Bialystok, 15-274 Bialystok, PolandDepartment of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, PolandDepartment of Gastroenterology and Internal Medicine, Medical University of Bialystok, 15-276 Bialystok, PolandPancreatic ductal adenocarcinoma is one of the deadliest human neoplasms. Despite the development of new surgical and adjuvant therapies, the prognosis remains very poor, with the overall survival rate not exceeding 9%. There is now increasing evidence that the human microbiome, which is involved in many physiological functions, including the regulation of metabolic processes and the modulation of the immune system, is possibly linked to pancreatic oncogenesis. However, the exact mechanisms of action are poorly understood. Our review summarizes the current understanding of how the microbiome affects pancreatic cancer development and progression. We discuss potential pathways of microbe translocation to the pancreas, as well as the mechanism of their action. We describe the role of the microbiome as a potential marker of pancreatic cancer diagnosis, progression, and survival. Finally, we discuss the possibilities of modifying the microbiome to improve treatment effectiveness for this deadly disease.https://www.mdpi.com/2077-0383/10/23/5624pancreatic cancermicrobiomeinflammationimmunotherapy |
| spellingShingle | Jaroslaw Daniluk Urszula Daniluk Pawel Rogalski Andrzej Dabrowski Agnieszka Swidnicka-Siergiejko Microbiome—Friend or Foe of Pancreatic Cancer? Journal of Clinical Medicine pancreatic cancer microbiome inflammation immunotherapy |
| title | Microbiome—Friend or Foe of Pancreatic Cancer? |
| title_full | Microbiome—Friend or Foe of Pancreatic Cancer? |
| title_fullStr | Microbiome—Friend or Foe of Pancreatic Cancer? |
| title_full_unstemmed | Microbiome—Friend or Foe of Pancreatic Cancer? |
| title_short | Microbiome—Friend or Foe of Pancreatic Cancer? |
| title_sort | microbiome friend or foe of pancreatic cancer |
| topic | pancreatic cancer microbiome inflammation immunotherapy |
| url | https://www.mdpi.com/2077-0383/10/23/5624 |
| work_keys_str_mv | AT jaroslawdaniluk microbiomefriendorfoeofpancreaticcancer AT urszuladaniluk microbiomefriendorfoeofpancreaticcancer AT pawelrogalski microbiomefriendorfoeofpancreaticcancer AT andrzejdabrowski microbiomefriendorfoeofpancreaticcancer AT agnieszkaswidnickasiergiejko microbiomefriendorfoeofpancreaticcancer |